BERLIN & SAN DIEGO–(BUSINESS WIRE)–Bayer and Iambic Therapeutics Inc., a clinical-stage life science and technology company developing novel medicines using its AI-driven platform, today announced a drug discovery collaboration in which Bayer will discover new medicines using Iambic’s AI-driven platform. The collaboration is focused on small molecule discovery. The collaboration will leverage Iambic’s AI-driven drug discovery platform, including its flagship AI technologies, Enchant & Neu
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
